<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38458016</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1360</ISSN><JournalIssue CitedMedium="Internet"><Volume>179</Volume><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of psychosomatic research</Title><ISOAbbreviation>J Psychosom Res</ISOAbbreviation></Journal><ArticleTitle>An open trial of biofeedback for long COVID.</ArticleTitle><Pagination><StartPage>111625</StartPage><MedlinePgn>111625</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychores.2024.111625</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3999(24)00037-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Biofeedback is a therapeutic treatment model that teaches self-regulation of autonomic functions to alleviate stress-related symptoms. "Long COVID" refers to chronic physical and cognitive sequelae post-SARS-CoV-2 infection. This study examined the efficacy of a six-week intervention, consisting of weekly one-hour sessions combining heart rate variability and temperature biofeedback, for alleviating mood symptoms, somatic symptoms and sleep disturbance of patients diagnosed with long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were collected from 20 adult participants aged 22-63 (M<sub>age</sub>&#xa0;=&#xa0;44.1, SD<sub>age</sub>&#xa0;=&#xa0;12.2) with varying long COVID symptoms. Within this single arm design, 16 of the 20 participants completed all six sessions of biofeedback; 14 completed an assessment at the three-month post-treatment time point.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants self-reported significant improvements in somatic, anxiety, and depressive symptoms, sleep quality, quality of life, and number of "bad days" immediately after the intervention and three months later (Cohen's d effect size (ES)&#xa0;=&#xa0;1.09-0.46). Reduced number of medical doctor visits (ES&#xa0;=&#xa0;0.85) and prescription drug use over the last month (odds ratio&#xa0;=&#xa0;0.33), as well as improved emotional wellbeing (ES&#xa0;=&#xa0;0.97) were observed at the three-month time point only.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Results suggest that this short, readily scalable intervention can be potentially efficacious in alleviating symptoms of long COVID. Despite notable improvements, the major limitation of this study is its lack of control group. While a randomized trial merits study, biofeedback appears to be a brief, effective, non-invasive, and low-cost treatment option for patients with chronic somatic symptoms secondary to SARS-CoV-2 infection.</AbstractText><AbstractText Label="CLINICALTRIALS" NlmCategory="RESULTS">govID: NCT05120648.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emerson</LastName><ForeName>Natacha D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>UCLA Psychiatry &amp; Biobehavioral Sciences, David Geffen School of Medicine, United States. Electronic address: NDEmerson@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavretsky</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UCLA Psychiatry &amp; Biobehavioral Sciences, David Geffen School of Medicine, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pittman</LastName><ForeName>William Q</ForeName><Initials>WQ</Initials><AffiliationInfo><Affiliation>UCLA Department of Medicine, David Geffen School of Medicine, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viswanathan</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>UCLA Department of Medicine, David Geffen School of Medicine, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddarth</LastName><ForeName>Prabha</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UCLA Psychiatry &amp; Biobehavioral Sciences, David Geffen School of Medicine, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05120648</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K24 AT009198</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychosom Res</MedlineTA><NlmUniqueID>0376333</NlmUniqueID><ISSNLinking>0022-3999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001676" MajorTopicYN="N">Biofeedback, Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biofeedback</Keyword><Keyword MajorTopicYN="N">Dysautonomia</Keyword><Keyword MajorTopicYN="N">Heart rate variability</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of SARS COV-2 infection (PASC)</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>9</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38458016</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychores.2024.111625</ArticleId><ArticleId IdType="pii">S0022-3999(24)00037-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>